Familial ApoB-specific familial hypobetalipoproteinemia in a patient with non-classical congenital adrenal hyperplasia.
Hipobetalipoproteinemia familiar ApoB específica en una paciente con hiperplasia suprarrenal congénita no clásica.
21-Hydroxylase
21-hidroxilasa
APOB gene
CYP21A2
Familial hypobetalipoproteinaemia
Gen APOB
Hiperplasia suprarrenal congénita no clásica
Hipobetalipoproteinemia familiar
Non-classical congenital adrenal hyperplasia
Journal
Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
ISSN: 1578-1879
Titre abrégé: Clin Investig Arterioscler
Pays: Spain
ID NLM: 9208512
Informations de publication
Date de publication:
08 Jan 2024
08 Jan 2024
Historique:
received:
25
09
2023
accepted:
14
12
2023
medline:
10
1
2024
pubmed:
10
1
2024
entrez:
9
1
2024
Statut:
aheadofprint
Résumé
Familial hypobetalipoproteinaemia is a disorder of lipid metabolism characterized by low levels of total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B. ApoB-related familial hypolipoproteinemia is an autosomal condition with a codominance inheritance pattern. Non-classical congenital adrenal hyperplasia is an autosomal recessive disorder due to mutations in the CYP21A2, a gene encoding for the enzyme 21-hydroxylase, which results in an androgen excess production from adrenal source. We here present the case of a 25-year-old woman with NCAH showing decreased levels of total-cholesterol, low-density lipoprotein cholesterol and triglycerides. Her parent had digestive symptoms and severe hepatic steatosis with elevated liver enzymes, as well as decreased levels of total and low-density lipoprotein cholesterol. A genetic-molecular study of the proband identified a mutation in the APOB gene, which allowed a diagnosis of heterozygous ApoB-related hypolipoproteinaemia to be made.
Identifiants
pubmed: 38195282
pii: S0214-9168(23)00117-1
doi: 10.1016/j.arteri.2023.12.002
pii:
doi:
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.